Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
0 hedge funds and large institutions have $0 invested in Fusion Pharmaceuticals Inc. Common Shares in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 112 closing their positions.
100% less funds holding
Funds holding: 114 → 0 (-114)
100% less funds holding in top 10
Funds holding in top 10: 8 → 0 (-8)
100% less capital invested
Capital invested by funds: $1.47B → $0 (-$1.47B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 112
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$230M |
| 2 |
PA
Perceptive Advisors
New York
|
-$146M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$139M |
| 4 |
DM
Deerfield Management
New York
|
-$136M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$89.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$112K | -5,252 | Closed |
|
|
S
102
SignatureFD
Atlanta,
Georgia
| – | -$62.9K | -2,949 | Closed |
|
103
Wells Fargo
San Francisco,
California
| – | -$32K | -1,500 | Closed |
|
104
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$20K | -924 | Closed |
|
|
TWC
105
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$14.9K | -700 | Closed |
|
|
TRCT
106
Tower Research Capital (TRC)
New York
| – | -$10.8K | -508 | Closed |
|
|
TFA
107
Toth Financial Advisory
Leesburg,
Virginia
| – | -$10.7K | -501 | Closed |
|
|
EC
108
EntryPoint Capital
New York
| – | -$7.44K | -349 | Closed |
|
109
Daiwa Securities Group
Tokyo,
Japan
| – | -$6K | -268 | Closed |
|
110
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.83K | -86 | Closed |
|
|
GI
111
GAMMA Investing
Foster City,
California
| – | -$554 | -26 | Closed |
|
|
SA
112
Scarborough Advisors
Annapolis,
Maryland
| – | -$277 | -13 | Closed |
|
FUSN Hedge Fund Activity: Q2 2024 in Review
0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2024, worth a combined $0 — down 100% from $1.47B a quarter earlier.
Sellers outnumbered buyers: 112 funds closed out of FUSN and 0 opened new positions — a net loss of 112 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Federated Hermes, exiting entirely with an estimated $230M sold.
- 0 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2024, down from 114 in Q1 2024.
- Funds reported $0 of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2024 and 112 closed out, a net change of -112 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q2 2024 was Federated Hermes, an estimated $230M sold.
Based on aggregated 13F filings for Q2 2024.